Ye. P. Boguslavskyi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ye. P. Boguslavskyi has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Andriy Goy
Київський національний університет технологій та дизайну, АТ «Фармак
3 shared publications - Halyna Voskoboinikova
Kyiv International University; JSC Farmak
2 shared publications - Gureyeva
Київський національний університет технологій та дизайну, АТ «Фармак
1 shared publication H. L. Voskoboynikova
АТ «Фармак», Україна; Київський міжнародний університет, Україна
1 shared publication- Natela Dovzhuk
Bogomolets National Medical University
1 shared publication - Oksana Tryhubchak
АТ «Фармак
1 shared publication
Latest Publications
- Open Access
- 1 April 2026
- Published by National University of Pharmacy in Social Pharmacy in Health Care
- Vol. 12 (1) , 92-104
The analysis of the current state and prospects for the development of the pharmaceutical market of gliflozin derivatives in Ukraine
One of the most pressing medical and social problems of our time is the treatment and prevention of diabetes mellitus. The development of chronic hyperglycemia leads to damage, dysfunction and insufficiency of organs, in particular the eyes, kidneys, nervous system, heart and blood vessels, as well as complicates wound healing processes and increases the risk of infectious complications. Drugs of the group of sodium-glucose cotransporter 2 (SGLT2) inhibitors are promising due to their focus on the comprehensive treatment of diabetes symptoms compared to reference drugs that had an exclusively hypoglycemic effect. However, drugs of the SGLT2 group are new and protected by the patent for at least the next 7-10 years. The patent protection restricts the commercial production of generic products, but at the same time is not an obstacle to scientific research. Before making a decision to start them, an important step is to analyze the current state of the market. Aim. To conduct a comprehensive pharmaceutical and marketing analysis of the market of sodium-glucose cotransporter-2 (SGLT2) inhibitors, particularly gliflozin derivatives, with the assessment of their range, structure, pricing policy, and development prospects in the pharmaceutical market of Ukraine. Materials and methods. The study applied methods of the system analysis, content analysis, comparative and marketing analysis. The information base included data from the State Register of Medicines of Ukraine, analytical reviews of the pharmaceutical market, international scientific publications, as well as regulatory reference materials. The analysis was performed according to the ATC classification (group A10B, subgroup A10BK). Methods of the scientific analysis were used to evaluate recent scientific and practical publications. The results obtained were summarized using schematic visualization tools. Results and discussion. According to the results of the study it has been found that, as of 2025, the Ukrainian pharmaceutical market of SGLT2 inhibitors is represented exclusively by imported medicinal products, primarily based on dapagliflozin and empagliflozin, including fixed-dose combinations with metformin. It has been determined that the market is characterized by a limited assortment, the absence of domestic production, and high prices, which reduces the patient access to therapy. Global trends indicate steady growth of the gliflozin market and expansion of therapeutic indications. The patent protection has been identified as a key factor restraining the development of the generic segment in Ukraine. Conclusions. According to the results of the analysis, the SGLT2 inhibitors market in Ukraine is at the stage of formation and is characterized by import dependence and limited accessibility for patients. The expiration of the patent protection period creates favorable conditions for the development of domestic production of generic medicines of this group. This will contribute to improved treatment accessibility, reduced therapy costs, and the development of the national pharmaceutical sector.
- 1 April 2026
- Published by National University of Pharmacy in Social Pharmacy in Health Care
- Vol. 12 (1) , 92-104
Open AccessThe analysis of the current state and prospects for the development of the pharmaceutical market of gliflozin derivatives in Ukraine
One of the most pressing medical and social problems of our time is the treatment and prevention of diabetes mellitus. The development of chronic hyperglycemia leads to damage, dysfunction and insufficiency of organs, in particular the eyes, kidneys, nervous system, heart and blood vessels, as well as complicates wound healing processes and increases the risk of infectious complications. Drugs of the group of sodium-glucose cotransporter 2 (SGLT2) inhibitors are promising due to their focus on the comprehensive treatment of diabetes symptoms compared to reference drugs that had an exclusively hypoglycemic effect. However, drugs of the SGLT2 group are new and protected by the patent for at least the next 7-10 years. The patent protection restricts the commercial production of generic products, but at the same time is not an obstacle to scientific research. Before making a decision to start them, an important step is to analyze the current state of the market. Aim. To conduct a comprehensive pharmaceutical and marketing analysis of the market of sodium-glucose cotransporter-2 (SGLT2) inhibitors, particularly gliflozin derivatives, with the assessment of their range, structure, pricing policy, and development prospects in the pharmaceutical market of Ukraine. Materials and methods. The study applied methods of the system analysis, content analysis, comparative and marketing analysis. The information base included data from the State Register of Medicines of Ukraine, analytical reviews of the pharmaceutical market, international scientific publications, as well as regulatory reference materials. The analysis was performed according to the ATC classification (group A10B, subgroup A10BK). Methods of the scientific analysis were used to evaluate recent scientific and practical publications. The results obtained were summarized using schematic visualization tools. Results and discussion. According to the results of the study it has been found that, as of 2025, the Ukrainian pharmaceutical market of SGLT2 inhibitors is represented exclusively by imported medicinal products, primarily based on dapagliflozin and empagliflozin, including fixed-dose combinations with metformin. It has been determined that the market is characterized by a limited assortment, the absence of domestic production, and high prices, which reduces the patient access to therapy. Global trends indicate steady growth of the gliflozin market and expansion of therapeutic indications. The patent protection has been identified as a key factor restraining the development of the generic segment in Ukraine. Conclusions. According to the results of the analysis, the SGLT2 inhibitors market in Ukraine is at the stage of formation and is characterized by import dependence and limited accessibility for patients. The expiration of the patent protection period creates favorable conditions for the development of domestic production of generic medicines of this group. This will contribute to improved treatment accessibility, reduced therapy costs, and the development of the national pharmaceutical sector.
- Open Access
- 31 March 2025
- Published by Ternopil State Medical University in Фармацевтичний часопис
- No. 1,p. 24-31
ВИКОРИСТАННЯ МЕТОДУ ВИПАДКОВОГО БАЛАНСУ ДЛЯ РОЗРОБКИ КІЛЬКІСНОГО СКЛАДУ ТАБЛЕТОК ДАПАГЛІФЛОЗИНУ
Метою роботи було вивчення впливу кількості допоміжних речовин на показники якості таблетмас та таблеток дапагліфлозину методом випадкового балансу. Матеріали і методи. Для дослідження використовували дапагліфлозину пропандіолу моногідрат, МКЦ 102, лактоза безводна, кросповідон XL-10, кремнію діоксид колоїдний безводний (аеросил 200), магнію стеарат. Рецептури розроблені за методом випадкового балансу. Таблетки дапагліфлозину 5 мг виготовляли методом прямого пресування. Для характеристики якості отриманої лікарської форми їх аналізували відповідно до загальних фармакопейних статей на порошки і таблетки. Дослідження проведено на сучасному обладнанні. Результати і обговорення. Насипна густина і густина після ущільнення таблетмас покращувалися зі збільшенням кількості безводної лактози 22 AN. Значення кута природнього відкосу та розпадання таблеток залежали від кількості кросповідону XL-10. Зменшення кількості аеросилу 200 збільшує насипну густину і густину після ущільнення, покращує сипучість і кут природнього відкосу таблетмас. Вищу стійкість таблеток дапагліфлозину до роздавлювання досягали при застосуванні меншої кількості магнію стеарату. Висновки. За допомогою методу випадкового балансу вивчено кількість 4 допоміжних речовин на 3 рівнях. За результатами дослідження встановлено, що переваги за ознаками якості отримані при використанні 30,365 мг лактози безводної 22 АН, 5 мг кросповідону XL-10, 1,25 мг діоксиду кремнію колоїдного безводного (аеросил 200) та 0,625 мг магнію стеарату в розрахунку на 1 таблетку. В результаті експериментальних досліджень запропоновано оптимальний склад таблеток-ядер дапагліфлозин 5 мг.
- 31 March 2025
- Published by Ternopil State Medical University in Фармацевтичний часопис
- No. 1,p. 24-31
Open AccessВИКОРИСТАННЯ МЕТОДУ ВИПАДКОВОГО БАЛАНСУ ДЛЯ РОЗРОБКИ КІЛЬКІСНОГО СКЛАДУ ТАБЛЕТОК ДАПАГЛІФЛОЗИНУ
Метою роботи було вивчення впливу кількості допоміжних речовин на показники якості таблетмас та таблеток дапагліфлозину методом випадкового балансу. Матеріали і методи. Для дослідження використовували дапагліфлозину пропандіолу моногідрат, МКЦ 102, лактоза безводна, кросповідон XL-10, кремнію діоксид колоїдний безводний (аеросил 200), магнію стеарат. Рецептури розроблені за методом випадкового балансу. Таблетки дапагліфлозину 5 мг виготовляли методом прямого пресування. Для характеристики якості отриманої лікарської форми їх аналізували відповідно до загальних фармакопейних статей на порошки і таблетки. Дослідження проведено на сучасному обладнанні. Результати і обговорення. Насипна густина і густина після ущільнення таблетмас покращувалися зі збільшенням кількості безводної лактози 22 AN. Значення кута природнього відкосу та розпадання таблеток залежали від кількості кросповідону XL-10. Зменшення кількості аеросилу 200 збільшує насипну густину і густину після ущільнення, покращує сипучість і кут природнього відкосу таблетмас. Вищу стійкість таблеток дапагліфлозину до роздавлювання досягали при застосуванні меншої кількості магнію стеарату. Висновки. За допомогою методу випадкового балансу вивчено кількість 4 допоміжних речовин на 3 рівнях. За результатами дослідження встановлено, що переваги за ознаками якості отримані при використанні 30,365 мг лактози безводної 22 АН, 5 мг кросповідону XL-10, 1,25 мг діоксиду кремнію колоїдного безводного (аеросил 200) та 0,625 мг магнію стеарату в розрахунку на 1 таблетку. В результаті експериментальних досліджень запропоновано оптимальний склад таблеток-ядер дапагліфлозин 5 мг.
- Open Access
- 30 June 2024
- Published by Private Company Technology Center in ScienceRise: Pharmaceutical Science
- No. 3 (49),p. 86-95
Study of the identity of the polymorphic form of API – dapagliflosin derivative and of its permanency structure under the influence of the tableting process
The aim. To investigate the polymorphic structure of the API – Dapagliflozin propanediol monohydrate and to reveal the absence of an effect of the tabletting process on the polymorphic structure of the API in model compositions of tablets. Materials and methods. Model mixtures of API - dapagliflozin propanediol monohydrate and excipients were studied. The research used the method of designing pharmaco-technological parameters of solid dosage forms, the method of quantum-chemical modelling of the mechanical properties of polymorphic modifications of APIs, the modelling of shear deformation, the nanoindentation method, the Rietveld method for calculating X-ray patterns, X-ray structural analysis of API and selected model compositions of tablets. Results. The polymorphic structure of API - dapagliflozin propanediol monohydrate and its polymorphic structure in selected model compositions of tablets produced by the pressing method were studied and analyzed. An X-ray structural study was carried out, and the qualitative and phase composition of samples and polymorphic modifications of API and model series of tablets were determined. According to the results of the X-ray structural analysis, it was established that there is no polymorphic transition and that the polymorphic structure of API is invariant under the influence of pressing pressure, which ensures the quality of the tablet form. Conclusions. The design of an experimental study was determined based on the application of the QbD concept, design of experiments – DoE, for designing and ensuring a high-quality technological process – tabletting of API - Dapagliflozin propanediol monohydrate and excipients. To manage a critical technological parameter - the stability of the polymorphic structure of the API, which guarantees the quality of the tablet form, its bioavailability and bioequivalence, it is necessary to use a set of methods for studying structural changes and polymorphic modifications of the API during the tableting process. According to the results of the X-ray structural study of API and selected model compositions of tablets, it was established that during the process of tabletting under pressure, the structure of the polymorphic modification of dapagliflozin propanediol monohydrate does not change, and no polymorphic transition is observed
- 30 June 2024
- Published by Private Company Technology Center in ScienceRise: Pharmaceutical Science
- No. 3 (49),p. 86-95
Open AccessStudy of the identity of the polymorphic form of API – dapagliflosin derivative and of its permanency structure under the influence of the tableting process
The aim. To investigate the polymorphic structure of the API – Dapagliflozin propanediol monohydrate and to reveal the absence of an effect of the tabletting process on the polymorphic structure of the API in model compositions of tablets. Materials and methods. Model mixtures of API - dapagliflozin propanediol monohydrate and excipients were studied. The research used the method of designing pharmaco-technological parameters of solid dosage forms, the method of quantum-chemical modelling of the mechanical properties of polymorphic modifications of APIs, the modelling of shear deformation, the nanoindentation method, the Rietveld method for calculating X-ray patterns, X-ray structural analysis of API and selected model compositions of tablets. Results. The polymorphic structure of API - dapagliflozin propanediol monohydrate and its polymorphic structure in selected model compositions of tablets produced by the pressing method were studied and analyzed. An X-ray structural study was carried out, and the qualitative and phase composition of samples and polymorphic modifications of API and model series of tablets were determined. According to the results of the X-ray structural analysis, it was established that there is no polymorphic transition and that the polymorphic structure of API is invariant under the influence of pressing pressure, which ensures the quality of the tablet form. Conclusions. The design of an experimental study was determined based on the application of the QbD concept, design of experiments – DoE, for designing and ensuring a high-quality technological process – tabletting of API - Dapagliflozin propanediol monohydrate and excipients. To manage a critical technological parameter - the stability of the polymorphic structure of the API, which guarantees the quality of the tablet form, its bioavailability and bioequivalence, it is necessary to use a set of methods for studying structural changes and polymorphic modifications of the API during the tableting process. According to the results of the X-ray structural study of API and selected model compositions of tablets, it was established that during the process of tabletting under pressure, the structure of the polymorphic modification of dapagliflozin propanediol monohydrate does not change, and no polymorphic transition is observed
- Open Access
- 8 May 2024
- Published by State Institution of Science "Center of Innovative Healthcare Technologies" State Administrative Department in Clinical and Preventive Medicine
- No. 3,p. 13-20
ASPECTS OF THE USE OF ANTIDIABETIC DRUGS IN PHARMACEUTICAL PRACTICE ON THE BASIS OF RATIONAL PHARMACOTHERAPY
The aim of the article. To study of the incidence of diabetes mellitus in Ukraine and to determine the prospects for the use and pharmaceutical development of antidiabetic drugs. Materials and methods. Data from the State Registers of Medicinal Products of Ukraine, of Wholesale and Retail Prices for Medicinal Products declared in Ukraine under an international non-proprietary or generic name (01.01.2024). Were used: systematic and comparative analysis, processing and synthesis, and generalization to determine the forecasted prospects. Results. In Ukraine the number of diabetes patients increased by 11% in the group of children and adolescents; in the group of elderly patients – by 12.5%, among the adult working – 20%, diabetes of the II type predominates. The trend of increase in the number of studies on the search for therapeutic alternatives for the treatment of type II diabetes and list of medicines on the pharmaceutical market has been revealed. In Ukraine drugs for oral use include APIs of the following pharmacological groups: sulfonylureas; meglitinides; biguanides; thiazolidinedione; α-glucosidase inhibitors; DPP-4 inhibitors; SGLT-2 inhibitors. Mechanism of action of the new class of oral hypoglycemic agents, approved by the FDA, consists in blocking SGLT-2 proteins from the proximal convoluted tubule in the kidney, leads to the prevention of reabsorption and excretion of the glucose molecule. This allows its use in combination with insulin and other antidiabetic drugs for the treatment of type I and II diabetes in patients of various age categories. According to the volume of clinical studies, SGLT-2 inhibitor SGLT-2 derivative gliflozin API drugs are the second largest group of antidiabetic drugs recommended for use by FDA and EMA regulatory bodies. Conclusions. The pharmaceutical development of mono and combined drugs with APIs SGLT-2 inhibitors gliflozin derivatives in combination with APIs with metformin, DPP-4 inhibitors, APIs thiazolidinedione derivatives is promising for solving the problem of diabetes treatment and prevention of complications for patients of different age groups including working population in Ukraine.
- 8 May 2024
- Published by State Institution of Science "Center of Innovative Healthcare Technologies" State Administrative Department in Clinical and Preventive Medicine
- No. 3,p. 13-20
Open AccessASPECTS OF THE USE OF ANTIDIABETIC DRUGS IN PHARMACEUTICAL PRACTICE ON THE BASIS OF RATIONAL PHARMACOTHERAPY
The aim of the article. To study of the incidence of diabetes mellitus in Ukraine and to determine the prospects for the use and pharmaceutical development of antidiabetic drugs. Materials and methods. Data from the State Registers of Medicinal Products of Ukraine, of Wholesale and Retail Prices for Medicinal Products declared in Ukraine under an international non-proprietary or generic name (01.01.2024). Were used: systematic and comparative analysis, processing and synthesis, and generalization to determine the forecasted prospects. Results. In Ukraine the number of diabetes patients increased by 11% in the group of children and adolescents; in the group of elderly patients – by 12.5%, among the adult working – 20%, diabetes of the II type predominates. The trend of increase in the number of studies on the search for therapeutic alternatives for the treatment of type II diabetes and list of medicines on the pharmaceutical market has been revealed. In Ukraine drugs for oral use include APIs of the following pharmacological groups: sulfonylureas; meglitinides; biguanides; thiazolidinedione; α-glucosidase inhibitors; DPP-4 inhibitors; SGLT-2 inhibitors. Mechanism of action of the new class of oral hypoglycemic agents, approved by the FDA, consists in blocking SGLT-2 proteins from the proximal convoluted tubule in the kidney, leads to the prevention of reabsorption and excretion of the glucose molecule. This allows its use in combination with insulin and other antidiabetic drugs for the treatment of type I and II diabetes in patients of various age categories. According to the volume of clinical studies, SGLT-2 inhibitor SGLT-2 derivative gliflozin API drugs are the second largest group of antidiabetic drugs recommended for use by FDA and EMA regulatory bodies. Conclusions. The pharmaceutical development of mono and combined drugs with APIs SGLT-2 inhibitors gliflozin derivatives in combination with APIs with metformin, DPP-4 inhibitors, APIs thiazolidinedione derivatives is promising for solving the problem of diabetes treatment and prevention of complications for patients of different age groups including working population in Ukraine.
- Open Access
- 29 March 2024
- Published by National University of Pharmacy in News of Pharmacy
- Vol. 107 (1) , 110-118
A model design for managing technological parameters at the stage of the pharmaceutical development of antidiabetic drugs in the form of solid dosage forms
Aim. To develop a model for managing technological parameters at the stage of the pharmaceutical development of an antidiabetic drug in tablets with API of SGLT-2 class – a derivative of gliflozin. Materials and methods. In the study conducted, the methods of system and comparative analysis, generalization, statistical processing and synthesis were used in determining the projected prospects, design, modeling, mathematical modeling, tabular and graphic means of presenting the results. To implement the goals and objectives of the study, software and electronic resources of the Anatomical Therapeutically Chemical Classification System (ATC), Biopharmaceutical Classification System (BCS), Compendium, State Register of Medicines of Ukraine were used; statistical data and data from clinical studies of the content were as follows: https://www.wipo.int; https://www.dec.gov.ua; https://www.clinicaltrials.gov; https://www.ncbi.nlm. nih.gov; https://eacpt.org; https://bpspubs.onlinelibrary.wiley.com. The study was conducted on the modern equipment for determining the bulk density (ERWEKA SVM 202, Germany), the flowability of powders (ERWEKA GT, Germany), resistance to crushing (ERWEKA TBH-525 WTO, Germany), friability (ERWEKA TAR 200, Germany), disintegration (ERWEKA ZT 33, Germany). The active ingredient in tablets of the antidiabetic drug is API calculated with reference to the content of dapagliflozin, 5 mg. The following excipients from the groups of fillers (factor A) were used: a1 – microcrystalline cellulose (MCC) of grade 200, a2 – lactose monohydrate of grade 80, a3 – a mixture of MCC of grade 102 with anhydrous lactose of grade 22 AN in the ratio of 3:1; disintegrants (factor B): b1 – crospovidone XL-10, b2 – sodium croscarmellose, b3 – sodium starch glycolate, glidants (factor C): c1 – colloidal anhydrous silicon dioxide (aerosil 200), c2 – talc, c3 – polyethylene glycol (PEG) 8000, as well as magnesium stearate as a lubricant. The experimental data were subjected to statistical processing by the method of variance analysis. Results and discussion. The development and introduction of new pharmaceuticals, effective analogs and generics is an important task as it contributes to the improvement of the quality of drug supply, treatment and safe use for patients with diabetes mellitus. A model for managing technological parameters at the stage of the pharmaceutical development has been developed; the target quality profile of the antidiabetic drug and tablets with API of SGLT-2 class – a derivative of gliflozin has been substantiated, and critical quality indicators have been determined. According to the model proposed, the optimal composition and technology of antidiabetic tablets with API of SGLT-2 class – a derivative of gliflozin calculated with reference to dapagliflozin, 5 mg, have been developed using an experiment planning matrix based on a 3*3 hyper-Greek-Latin square of the second order; the excipients have been selected; the effect of qualitative and quantitative factors and technological parameters on the pharmaco-technological properties of the tablet masses studied and tablet quality indicators, as well as critical indicators of the quality of the pharmaceutical product have been determined. Experimental studies and risk assessment have been carried out; based on the results, the optimal parameters of the technological process for the production of the antidiabetic drug in tablets with API of SGLT-2 class – a derivative of gliflozin – dapagliflozin have been substantiated. Conclusions. Based on the results of the system analysis of the application of mathematical models in the production of pharmaceutical forms, it has been determined that mathematical modeling is a key stage for ensuring the quality of the technological process at the stage of the pharmaceutical development of an antidiabetic drug in tablets with API of SGLT-2 class – a derivative of gliflozin. The use of mathematical modeling in the course of the pharmaceutical development allows optimization at the stage of the experimental research of API, its polymorphic form, physico-chemical properties and pharmaco-technological indicators. A model for managing technological parameters at the stage of the pharmaceutical development has been proposed; the target quality profile of the antidiabetic drug and tablets with API of SGLT-2 class – a derivative of gliflozin has been substantiated; the optimal composition and technology of this pharmaceutical product has been developed. Мета дослідження – розробити модель управління технологічними параметрами на етапі фармацевтичної розробки препарату протидіабетичної дії в таблетках з АФІ класу SGLT-2 – похідним гліфлозину. Матеріали та методи. У здійсненому дослідженні використано методи системного й порівняльного аналізу, узагальнення, статистичної обробки й синтезу у визначенні прогнозованих перспектив, проєктування, моделювання, математичне моделювання, табличні і графічні засоби презентації результатів. Для реалізації мети і завдань дослідження використано програмні та електронні ресурси ATC (Anatomical Therapeutically Chemical Classification System), BCS (Biopharmaceutical Classification System), Сompendium, Державного реєстру лікарських засобів України; статистичні дані і дані клінічних досліджень контентів: https://www.wipo.int; https://www.dec.gov.ua;...
- 29 March 2024
- Published by National University of Pharmacy in News of Pharmacy
- Vol. 107 (1) , 110-118
Open AccessA model design for managing technological parameters at the stage of the pharmaceutical development of antidiabetic drugs in the form of solid dosage forms
Aim. To develop a model for managing technological parameters at the stage of the pharmaceutical development of an antidiabetic drug in tablets with API of SGLT-2 class – a derivative of gliflozin. Materials and methods. In the study conducted, the methods of system and comparative analysis, generalization, statistical processing and synthesis were used in determining the projected prospects, design, modeling, mathematical modeling, tabular and graphic means of presenting the results. To implement the goals and objectives of the study, software and electronic resources of the Anatomical Therapeutically Chemical Classification System (ATC), Biopharmaceutical Classification System (BCS), Compendium, State Register of Medicines of Ukraine were used; statistical data and data from clinical studies of the content were as follows: https://www.wipo.int; https://www.dec.gov.ua; https://www.clinicaltrials.gov; https://www.ncbi.nlm. nih.gov; https://eacpt.org; https://bpspubs.onlinelibrary.wiley.com. The study was conducted on the modern equipment for determining the bulk density (ERWEKA SVM 202, Germany), the flowability of powders (ERWEKA GT, Germany), resistance to crushing (ERWEKA TBH-525 WTO, Germany), friability (ERWEKA TAR 200, Germany), disintegration (ERWEKA ZT 33, Germany). The active ingredient in tablets of the antidiabetic drug is API calculated with reference to the content of dapagliflozin, 5 mg. The following excipients from the groups of fillers (factor A) were used: a1 – microcrystalline cellulose (MCC) of grade 200, a2 – lactose monohydrate of grade 80, a3 – a mixture of MCC of grade 102 with anhydrous lactose of grade 22 AN in the ratio of 3:1; disintegrants (factor B): b1 – crospovidone XL-10, b2 – sodium croscarmellose, b3 – sodium starch glycolate, glidants (factor C): c1 – colloidal anhydrous silicon dioxide (aerosil 200), c2 – talc, c3 – polyethylene glycol (PEG) 8000, as well as magnesium stearate as a lubricant. The experimental data were subjected to statistical processing by the method of variance analysis. Results and discussion. The development and introduction of new pharmaceuticals, effective analogs and generics is an important task as it contributes to the improvement of the quality of drug supply, treatment and safe use for patients with diabetes mellitus. A model for managing technological parameters at the stage of the pharmaceutical development has been developed; the target quality profile of the antidiabetic drug and tablets with API of SGLT-2 class – a derivative of gliflozin has been substantiated, and critical quality indicators have been determined. According to the model proposed, the optimal composition and technology of antidiabetic tablets with API of SGLT-2 class – a derivative of gliflozin calculated with reference to dapagliflozin, 5 mg, have been developed using an experiment planning matrix based on a 3*3 hyper-Greek-Latin square of the second order; the excipients have been selected; the effect of qualitative and quantitative factors and technological parameters on the pharmaco-technological properties of the tablet masses studied and tablet quality indicators, as well as critical indicators of the quality of the pharmaceutical product have been determined. Experimental studies and risk assessment have been carried out; based on the results, the optimal parameters of the technological process for the production of the antidiabetic drug in tablets with API of SGLT-2 class – a derivative of gliflozin – dapagliflozin have been substantiated. Conclusions. Based on the results of the system analysis of the application of mathematical models in the production of pharmaceutical forms, it has been determined that mathematical modeling is a key stage for ensuring the quality of the technological process at the stage of the pharmaceutical development of an antidiabetic drug in tablets with API of SGLT-2 class – a derivative of gliflozin. The use of mathematical modeling in the course of the pharmaceutical development allows optimization at the stage of the experimental research of API, its polymorphic form, physico-chemical properties and pharmaco-technological indicators. A model for managing technological parameters at the stage of the pharmaceutical development has been proposed; the target quality profile of the antidiabetic drug and tablets with API of SGLT-2 class – a derivative of gliflozin has been substantiated; the optimal composition and technology of this pharmaceutical product has been developed. Мета дослідження – розробити модель управління технологічними параметрами на етапі фармацевтичної розробки препарату протидіабетичної дії в таблетках з АФІ класу SGLT-2 – похідним гліфлозину. Матеріали та методи. У здійсненому дослідженні використано методи системного й порівняльного аналізу, узагальнення, статистичної обробки й синтезу у визначенні прогнозованих перспектив, проєктування, моделювання, математичне моделювання, табличні і графічні засоби презентації результатів. Для реалізації мети і завдань дослідження використано програмні та електронні ресурси ATC (Anatomical Therapeutically Chemical Classification System), BCS (Biopharmaceutical Classification System), Сompendium, Державного реєстру лікарських засобів України; статистичні дані і дані клінічних досліджень контентів: https://www.wipo.int; https://www.dec.gov.ua;...
- Open Access
- 19 May 2023
- Published by National University of Pharmacy in Social Pharmacy in Health Care
- Vol. 9 (1) , 72-83
Analysis of trends in the positioning of pharmaceutical drugs of the SGLT-2 class of gliflozin derivatives at the pharmaceutical market and the application prospects
Aim – is to analyze trends in the use and positioning of pharmaceuticals of the class of gliflozin derivatives on the Ukrainian pharmaceutical market. Materials and methods. In the conducted research, the methods of systematic and comparative analysis, generalization, statistical processing and synthesis were used in determining the projected perspectives, tabular and graphic means of presenting the results. To implement the goal and objectives of the research, software and electronic resources of ATX (Anatomical-Therapeutically-Chemical), ATC (Anatomical Therapeutically Chemical Classification System), BSC (Biopharmaceutical Classification System), Vidal, Compendium, and the State Register of Medicinal Products of Ukraine were used. Results of the research. The results of a systematic analysis of application trends and a comparative analysis of marketing research on the positioning of pharmaceuticals of the class of gliflozin derivatives on regulated markets and the Ukrainian pharmaceutical market are presented. A steady trend in the positioning of the number of appointments in the segments of mono and combined drugs and the number of sales on regulated markets was revealed. It is established that as of the end of 2022, the total number of pharmaceuticals from API class SGLT-2 pharmaceutically acceptable of gliflozin derivatives in the form of solid dosage forms, which are positioned on regulated markets and pharmaceutical campaign research on the pharmaceutical development of new dosage forms of mono and combined drugs is 35, the number of registered pharmaceutical drugs in Ukraine is 4 mono and 2 combined drugs. The segment of this group of drugs - mono and combined drugs - has been systematized, according to the ATX classification by active substances - API - pharmaceutically acceptable salts of gliflozin derivatives on regulated markets and on the pharmaceutical market of Ukraine. Conclusions. The analysis of positioning on regulated markets and statistics of R&D research of pharmaceutical companies for the development of new dosage forms of mono and combined drugs provides grounds to generalize and conclude that SGLT-2 inhibitors are the newest and promising class of antidiabetic drugs, which, according to evidence-based medicine, are used in combination with with insulin and other antidiabetic drugs in the treatment of diabetes mellitus (DM) of I and II types, in combined regimens with metformin and DPP-4 inhibitors, as well as in combinations of all three and TZD drugs. SGLT-2 inhibitors are the second largest group of antidiabetic agents by the volume of clinical trials, which is 12%. Recommended for use by FDA regulatory authorities, EMA is an API of the SGLT-2 class of pharmaceutically acceptable derivatives of gliflozin: canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, tofogliflozin, sotagliflozin, as well as pharmaceutically acceptable salts; remogliflozin etabonate; sergliflozin etabonate. It has been established that SGLT-2 API drugs of pharmaceutically acceptable derivatives of gliflozin have a constant trend of positioning the number of appointments in the segments of mono and combined drugs and the number of sales on regulated markets, the total amount is 35 in the form of solid dosage forms. Distribution by volume of sales of solid dosage forms of pharmaceutical preparations with API class SGLT-2 of pharmaceutically acceptable of gliflozin derivatives is: tableted monopreparations – 59.2%; combined – 37.2%; mono preparations, hard capsules - 3.6%. The number of registered pharmaceutical drugs in Ukraine is 4 mono and 2 combined drugs, the level of prices from a pharmacoeconomic point of view, according to the results of price comparison of other antihyperglycemic drugs, are not affordable for Ukrainian patients who need systemic use. Therefore, the increase in the range of SGLT-2 class API drugs of pharmaceutically acceptable gliflozin derivatives on the Ukrainian pharmaceutical market and competitive manufacturers will contribute to the availability of use for the treatment of DM in Ukrainian patients. Key words: trends; positioning; application; pharmaceutically acceptable derivatives of gliflozin; drug support; best practice; evidence-based medicine; rational pharmacotherapy.
- 19 May 2023
- Published by National University of Pharmacy in Social Pharmacy in Health Care
- Vol. 9 (1) , 72-83
Open AccessAnalysis of trends in the positioning of pharmaceutical drugs of the SGLT-2 class of gliflozin derivatives at the pharmaceutical market and the application prospects
Aim – is to analyze trends in the use and positioning of pharmaceuticals of the class of gliflozin derivatives on the Ukrainian pharmaceutical market. Materials and methods. In the conducted research, the methods of systematic and comparative analysis, generalization, statistical processing and synthesis were used in determining the projected perspectives, tabular and graphic means of presenting the results. To implement the goal and objectives of the research, software and electronic resources of ATX (Anatomical-Therapeutically-Chemical), ATC (Anatomical Therapeutically Chemical Classification System), BSC (Biopharmaceutical Classification System), Vidal, Compendium, and the State Register of Medicinal Products of Ukraine were used. Results of the research. The results of a systematic analysis of application trends and a comparative analysis of marketing research on the positioning of pharmaceuticals of the class of gliflozin derivatives on regulated markets and the Ukrainian pharmaceutical market are presented. A steady trend in the positioning of the number of appointments in the segments of mono and combined drugs and the number of sales on regulated markets was revealed. It is established that as of the end of 2022, the total number of pharmaceuticals from API class SGLT-2 pharmaceutically acceptable of gliflozin derivatives in the form of solid dosage forms, which are positioned on regulated markets and pharmaceutical campaign research on the pharmaceutical development of new dosage forms of mono and combined drugs is 35, the number of registered pharmaceutical drugs in Ukraine is 4 mono and 2 combined drugs. The segment of this group of drugs - mono and combined drugs - has been systematized, according to the ATX classification by active substances - API - pharmaceutically acceptable salts of gliflozin derivatives on regulated markets and on the pharmaceutical market of Ukraine. Conclusions. The analysis of positioning on regulated markets and statistics of R&D research of pharmaceutical companies for the development of new dosage forms of mono and combined drugs provides grounds to generalize and conclude that SGLT-2 inhibitors are the newest and promising class of antidiabetic drugs, which, according to evidence-based medicine, are used in combination with with insulin and other antidiabetic drugs in the treatment of diabetes mellitus (DM) of I and II types, in combined regimens with metformin and DPP-4 inhibitors, as well as in combinations of all three and TZD drugs. SGLT-2 inhibitors are the second largest group of antidiabetic agents by the volume of clinical trials, which is 12%. Recommended for use by FDA regulatory authorities, EMA is an API of the SGLT-2 class of pharmaceutically acceptable derivatives of gliflozin: canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, tofogliflozin, sotagliflozin, as well as pharmaceutically acceptable salts; remogliflozin etabonate; sergliflozin etabonate. It has been established that SGLT-2 API drugs of pharmaceutically acceptable derivatives of gliflozin have a constant trend of positioning the number of appointments in the segments of mono and combined drugs and the number of sales on regulated markets, the total amount is 35 in the form of solid dosage forms. Distribution by volume of sales of solid dosage forms of pharmaceutical preparations with API class SGLT-2 of pharmaceutically acceptable of gliflozin derivatives is: tableted monopreparations – 59.2%; combined – 37.2%; mono preparations, hard capsules - 3.6%. The number of registered pharmaceutical drugs in Ukraine is 4 mono and 2 combined drugs, the level of prices from a pharmacoeconomic point of view, according to the results of price comparison of other antihyperglycemic drugs, are not affordable for Ukrainian patients who need systemic use. Therefore, the increase in the range of SGLT-2 class API drugs of pharmaceutically acceptable gliflozin derivatives on the Ukrainian pharmaceutical market and competitive manufacturers will contribute to the availability of use for the treatment of DM in Ukrainian patients. Key words: trends; positioning; application; pharmaceutically acceptable derivatives of gliflozin; drug support; best practice; evidence-based medicine; rational pharmacotherapy.